$MNOV still climbing. Pr
Nasdaq $7.70
Called 9/2/14
$MNOV still climbing. Pr
Nasdaq $7.70
Called 9/2/14 $2.35
MediciNova Receives Notice of Allowance
for New Patent Covering MN-001 in China
GlobeNewswire (Sun, Mar 27)
Website
Shares Outstanding: 30.00M
Float: 26.74M
% Held by Insiders: 22.50%
% Held by Institutions: 8.50%
Shares Short (as of Mar 15, 2016): 1.52M
Short Ratio (as of Mar 15, 2016): 4.31
Short % of Float (as of Mar 15, 2016): 6.98%
Shares Short (prior month): 1.16M
Headlines
Company Profile - MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166 (Ibudilast), an anti-inflammatory and neuroprotective agent, which has completed Phase II clinical trials for the treatment of neurological disorders; MN-221 (Bedoradrine), a ß2-adrenergic receptor agonist that has completed Phase IIb clinical trails for the treatment of acute exacerbations of asthma; MN-001 (Tipelukast), an orally bioavailable small molecule compound, which has completed a pre-clinical study for the treatment of nonalcoholic steatohepatitis; and MN-029 (Denibulin), a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.
MediciNova Inc. (MNOV) Stock Research Links
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Western Microsurgical's Bold Moves Western Microsurgical (WMS) is out here making waves, pulling off some serious strategic plays with the acquisitions of Q Surgical and Proficient Surgical. Now, this ain't some fly-by-night decision—this is about securing territory and leveling up their game in surgical microscopes and operating room supplies. With a footprint that'll...
Continue Reading
Revitalizing a Strategic Partnership Monday's meeting of the U.S.-Saudi Business Council wasn't just another gathering of suits; it was about re-kindling the investment flame between these two economic giants. Chaired by powerhouses Lubna Olayan and Jane Fraser, this wasn't a mere photo op. It was a call to arms in a landscape riddled with hurdles but bursting with...
Continue Reading
Is DexCom’s Leadership Under The Gun? Here's the scoop, folks—DexCom, Inc. (NASDAQ:DXCM) has been hit with some serious questions recently. Nothing like a potential fiduciary breach to shake things up. October 27, 2026, is when the news broke, with Halper Sadeh LLC taking the reins on this investigation. They’re poking around to see if DexCom’s top dogs stumbled...
Continue Reading
A New Spin in Madera Cue the fanfare, folks! The North Fork Mono Casino just threw open its doors earlier than expected today, marking a hefty $750 million wager right in the heart of California's Central Valley. It's a big deal managed by Station Casinos, part of Red Rock Resorts, Inc. (NASDAQ: RRR)—teaming up with the North Fork Rancheria of Mono Indians for a...
Continue Reading
A Rough Tumble for DICK'S Sporting Goods Let's cut to the chase: DICK'S Sporting Goods, Inc. (NYSE:DKS) just took a nosedive. We're talking a hard 30.68% fall on the stock, plummeting to $124.31 a share as of August 25, 2026. Now, if you were caught up in this whirlwind as an investor, you'd be forgiven for having a few choice words for the powers that be over at DICK'S....
Continue Reading
Celebrating an AI Security Standout Well, look at that, Noma's found itself on the Fortune Cyber 60 list for 2026-2027. This listing isn't just some vanity metric. We’re talking about getting the nod from heavyweights like Lightspeed Venture Partners and Amazon Web Services. It recognizes them among 60 pivotal, venture-backed cybersecurity players, and sure, it’s in...
Continue Reading
An Eye on the Future: oToBrite's Bold Vision for Robotics Strolling down the aisles at ROBOTWORLD 2026, there's a palpable energy buzzing around oToBrite's booth. These folks are showcasing vision technology that's not just about snapping slick photos—it's about reshaping how machines see the world. And, let me tell you, if there’s one place to flaunt cutting-edge...
Continue Reading
A Closer Look at Bank Leumi's Upcoming Q3 Release Take a seat, folks. Bank Leumi’s gearing up to spill the beans on their Third Quarter 2026 earnings come November 17th. If you’re in the financial world, you might want to mark your calendar because these reports tend to shake things up. You know how these go - numbers rolling out, market responses, and plenty of...
Continue Reading
Jiahui's International Cell Therapy Center: A New Era Jiahui International Hospital is shaking up the healthcare scene with its fresh International Cell Therapy Center, diving headfirst into the cutting-edge world of CAR-T treatments. It's not every day you see this kind of bold move, especially from a player aiming to extend their reach both in China and abroad. Let's...
Continue Reading
New Contender in the Global Botulinum Toxin Arena Launching a fresh player onto the international stage, CELSET INC. from Seoul throws down with SOLTOX, their own botulinum toxin Type A brand. This ain't your run-of-the-mill roll-out; it's another notch for Korean biotech trying to snag a piece of global market action. A Look at SOLTOX's Technical Makeup We’re talking...
Continue Reading